EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Subretinal Tissue Plasminogen Activator Injection Using a Nanovitreoretinal Device for Massive Submacular Hemorrhage: A Retrospective Case Series

Jinsuk Chun, Young Je Choi, Tae Young Kim, Se Ik Park, Seung Min Lee, Eun Young Choi, Junwon Lee, Min Kim

Korean Journal of Ophthalmology · 05.08.2026 · 40 (4) · 384-395

DOI: 10.3341/kjo.2026.0084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Korean Journal of Ophthalmology, erschienen am 05.08.2026. Verfasst von Jinsuk Chun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Vision Research, Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Tissue Plasminogen Activator, Retinal Hemorrhage, Visual Acuity, Fibrinolytic Agents. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the efficacy of subretinal tissue plasminogen activator (tPA) injection in patients with massive submacular hemorrhage (SMH) with or without vitrectomy.

Methods

This retrospective study included patients with massive SMH treated with subretinal tPA injection (12.5 μg/0.1 mL) using a nanovitreoretinal (NVR) device at a single tertiary referral center between 2020 and 2024. Primary outcomes were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT); secondary outcomes included SMH thickness reduction and between-group comparison of surgical approaches.

Results

Eighteen eyes of 15 patients were analyzed; 11 eyes (61.1%) were from female patients. Twelve eyes underwent vitrectomy (66.7%), while six were treated without vitrectomy (33.3%). Baseline demographic and clinical characteristics were summarized descriptively because of the small and imbalanced subgroup sizes. Neovascular age-related macular degeneration was the leading etiology (17 eyes, 94.4%), comprising typical neovascular age-related macular degeneration (9 eyes, 50.0%), polypoidal choroidal vasculopathy (7 eyes, 38.9%), and retinal angiomatous proliferation (1 eye, 5.6%); the remaining eye (5.6%) had peripheral exudative hemorrhagic chorioretinopathy. BCVA improved significantly from 1.79 ± 0.77 to 1.28 ± 0.83 logMAR (p = 0.010), with 10 eyes (55.6%) achieving ≥3-line improvement. CMT decreased significantly at 6 months (673.8 ± 346.7 to 266.0 ± 327.1 μm, p = 0.019), and 81.3% of eyes achieved ≥20% CMT reduction. SMH thickness decreased significantly postinjection (536.9 ± 345.0 to 221.4 ± 443.4 μm, p = 0.020). No significant differences in final BCVA (1.24 ± 0.77 logMAR vs. 1.37 ± 1.01 logMAR, p = 0.850) or CMT reduction rate (81.8% vs. 80.0%; p > 0.999) were observed between vitrectomy and nonvitrectomy groups.

Conclusions

Subretinal tPA injection via the NVR device was associated with improvements in visual and anatomical outcomes in massive SMH. The nonvitrectomy approach showed no significant difference in outcomes compared with vitrectomy-assisted injection, but this exploratory finding should be interpreted cautiously given the small sample size.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tissue Plasminogen ActivatorRetinal HemorrhageVisual AcuityFibrinolytic AgentsHumansFemaleRetrospective StudiesMaleVitrectomyAgedTomography, Optical CoherenceMiddle AgedFluorescein AngiographyFollow-Up StudiesAged, 80 and overTreatment OutcomeInjections, Intraocular

Stichwörter der Autor:innen

Age-related macular degenerationChoroidal neovascularizationRetinal hemorrhageTissue plasminogen activatorVisual acuity

Substanzen

Tissue Plasminogen ActivatorFibrinolytic Agents

Autor:innen und Institutionen

  • Institute of Vision Research, Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Institute of Vision Research, Department of Ophthalmology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
  • Institute of Vision Research, Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. minkim76@yuhs.ac.

Zitieren

APA

Chun, J., Choi, Y. J., Kim, T. Y., Park, S. I., Lee, S. M., Choi, E. Y., Lee, J., & Kim, M. (2026). Subretinal Tissue Plasminogen Activator Injection Using a Nanovitreoretinal Device for Massive Submacular Hemorrhage: A Retrospective Case Series. Korean Journal of Ophthalmology, 40(4), 384-395. https://doi.org/10.3341/kjo.2026.0084

Vancouver

Chun J, Choi YJ, Kim TY, Park SI, Lee SM, Choi EY, et al. Subretinal Tissue Plasminogen Activator Injection Using a Nanovitreoretinal Device for Massive Submacular Hemorrhage: A Retrospective Case Series. Korean Journal of Ophthalmology. 2026;40(4):384-395. doi:10.3341/kjo.2026.0084

BibTeX
@article{Chun2026,
  author = {Chun, Jinsuk and Choi, Young Je and Kim, Tae Young and Park, Se Ik and Lee, Seung Min and Choi, Eun Young and Lee, Junwon and Kim, Min},
  title = {Subretinal Tissue Plasminogen Activator Injection Using a Nanovitreoretinal Device for Massive Submacular Hemorrhage: A Retrospective Case Series},
  journal = {Korean Journal of Ophthalmology},
  year = {2026},
  volume = {40},
  number = {4},
  pages = {384--395},
  doi = {10.3341/kjo.2026.0084}
}
Kostenlos starten →